NEW YORK – Researchers from the precision medicine Zero Childhood Cancer Program in Australia said they were able to use tumor and germline whole-genome sequencing (WGS), RNA sequencing, and methylome analysis to elucidate the molecular basis of tumors from high-risk pediatric patients, leading to some patients being able to receive targeted therapies.